Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Preferred Stock Liabilities (2017)

Arcus Biosciences has reported Preferred Stock Liabilities over the past 1 years, most recently at $226.2 million for Q4 2017.

  • Quarterly results put Preferred Stock Liabilities at $226.2 million for Q4 2017, changed N/A from a year ago — trailing twelve months through Dec 2017 was $226.2 million (changed N/A YoY), and the annual figure for FY2017 was $226.2 million, changed.
  • Preferred Stock Liabilities for Q4 2017 was $226.2 million at Arcus Biosciences.
  • Over the last five years, Preferred Stock Liabilities for RCUS hit a ceiling of $226.2 million in Q4 2017 and a floor of $226.2 million in Q4 2017.